AlphAIAlphAI — Financial news for AI agents
BenzingaMAY 14 min read$CNBX

Cannabis Stock Gainers And Losers From May 1, 2025 - FLUENT (OTC:CNTMF), CNBX Pharmaceuticals (OTC:CNBX)

Maple Leaf Green World MGWFF shares closed up 83.67% at $0.03 Elixinol Wellness ELLXF shares closed up 77.11% at $0.01 4Front Ventures FFNTF shares closed up 45.00% at $0.00 1933 Industries TGIFF shares closed up 42.86% at $0.01 SOL Global Investments SOLCF shares closed up 19.84% at $0.09

Original reporting
Benzinga · Benzinga Insights
Published May 1, 2025, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 2, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CNBX
Bullish
medium confidence
Mentioned
$CNBX · $CRBP
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$CNBXBullishMed
01

Why it matters

The recent gains across multiple tickers suggest increased investor confidence, possibly influenced by industry developments or favorable regulatory news.

02

Market read

The sector is currently experiencing bullish momentum, with multiple companies showing significant share price increases, indicating a positive short-term trading environment.

03

What to watch

Regulatory changes, market saturation, or macroeconomic factors could impact the sustainability of current bullish trends; technical indicators and broader market conditions should be monitored.

Relevance 6/10Timing: Short-term, within days to weeks

Background

The cannabis industry has experienced significant volatility and growth, with recent positive news and market sentiment driving share price surges.

Company-level read

Ticker impact

$CNBXBullishMedium confidence
Context

High relevance due to recent gains and inclusion in the top gainers list.

Expected impact

Possible continuation of upward trend in the near term.

Evidence & confidence

Strong recent gains and bullish sentiment support further movement, but technical confirmation needed.

$CRBPBullishLow confidence
Context

Low relevance with a 19.90% relevance score; minimal impact on overall market sentiment.

Expected impact

Likely minimal impact on broader market; focus on more relevant tickers.

Evidence & confidence

Lower relevance suggests limited market influence; technical analysis required for actionable insights.

Market effects

Sector

Positive sentiment in cannabis sector may boost related industries such as retail, manufacturing, and life sciences

Regional

Potential uplift in North American cannabis markets, especially in regions with legal reforms

Global

Limited; primarily regional effects with some influence on global cannabis industry sentiment

Counterpoint

What could challenge this read

The recent gains may be driven by speculative trading or short-term hype, risking a correction or pullback in the near future.

Key entities

  • Company
    Maple Leaf Green World

    Cannabis cultivation and production company.

  • Company
    Elixinol Wellness

    CBD and wellness product manufacturer.

  • Company
    4Front Ventures

    Cannabis retailer and producer.

  • Company
    1933 Industries

    Cannabis consumer products.

  • Investment Firm
    SOL Global Investments

    Invests in cannabis and related industries.

Read at source← All news

Related articles

SEP 15
$CRBPMedAI 9/10

Corbus Obesity Pill Shows 5% Weight Loss With Clean Safety Profile in Mid-Stage Trial — BigGo Finance

Corbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.

finance.biggo.com2 min
SEP 15
$CRBPMedAI 8/10

Obesity drug could have fewer side effects than GLP-1s

Corbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development

foodnavigator.com2 min
SEP 14
$CRBPHighAI 8/10

Why is Corbus Pharmaceuticals stock surging today?

Corbus Pharmaceuticals (CRBP) stock rose 14.4% pre-market after reporting positive Phase 1b trial results for its obesity drug CRB-913, showing significant weight loss and a favorable safety profile. The company plans to present full data in November and initiate a Phase 2 study in 2027. The stock had been near its 52-week low before the announcement.

investing.com2 min
SEP 14
$CRBPHighAI 9/10

Corbus Pharmaceuticals stock rises on obesity drug trial data

Corbus Pharmaceuticals (CRBP) shares rose 12% after reporting positive Phase 1b trial data for obesity drug CRB-913. The 60 mg dose showed 5% mean weight loss at 12 weeks. The trial enrolled 254 participants and tested three doses, all showing significant weight loss. The drug was generally well tolerated. Corbus plans to discuss further development with the FDA and start a Phase 2 study in early 2027.

investing.com2 min
SEP 14
$CRBPMedAI 9/10

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau obs

SEC EDGAR 8-K2 min